<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        294-212-14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2014
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        AGOUT 40 mg film-coated tablets
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        FEBUXOSTAT
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        106.00
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SPIMACO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        M04AA03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>AGOUT tablets the active substance febuxostat and are used to treat gout, which is associated with an excess of a chemical called uric acid (urate) in the body. In some people, the amount of uric acid builds up in the blood and may become too high to remain soluble. When this happens, urate crystals may form in and around the joints and kidneys. These crystals can cause sudden, severe pain, redness, warmth and swelling in a joint (known as a gout attack). Left untreated, larger deposits called tophi (TOE-FI) may form in and around joints. These tophi may cause joint and bone damage. AGOUT works by reducing uric acid levels. Keeping uric acid levels low by taking AGOUT once every day stops crystals building up, and over time it reduces symptoms. Keeping uric acid levels sufficiently low for a long enough period can also shrink tophi. AGOUT 120 mg tablets is also used to treat and prevent high blood levels of uric acid that may occur when you start to receive chemotherapy for blood cancers. When chemotherapy is given, cancer cells are destroyed, and uric acid levels increase in the blood accordingly, unless the formation of uric acid is prevented. AGOUT is for adults.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take AGOUT if you are:</strong></p><p>&bull; If you are allergic (hypersensitive) to Febuxostat, the active ingredient of Agout, or any of the other ingredients in these tablets.</p><p><strong>Take special care with AGOUT:</strong></p><p>Tell your doctor before you start to take this medicine: &bull; If you have or have had heart failure or heart problems (as in a clinical trial for those who have already established cardiovascular disease, there was an increase in cardiovascular death risk when compared with Allopurinol although other major cardiovascular events were nonsignificant between the two treatments). &bull; If you have or have had renal disease and/or serious allergic reaction to Allopurinol (a medication used for the treatment of Gout) &bull; If you have or have had liver disease or liver function test abnormalities &bull; If you are being treated for high uric acid levels as a result of cancer disease or Lesch-Nyhan syndrome (a rare inherited condition in which there is too much uric acid in the blood). &bull; If you have thyroid problems. Should you experience allergic reactions to AGOUT, stop taking this medicine (see also section 4). Possible symptoms of allergic reactions might be: &bull; rash including severe forms (e.g. blisters, nodules, itchy-, exfoliative rash), itchiness &bull; swelling of limbs or face &bull; difficulties in breathing &bull; fever with enlarged lymph nodes &bull; but also serious life threatening allergic conditions with cardiac and circulatory arrest. Your doctor might decide to permanently stop treatment with AGOUT. There have been rare reports of potentially life-threatening skin rashes (Stevens-Johnson Syndrome) with the use of AGOUT, appearing initially as reddish target-like spots or circular patches often with central blister on the trunk. It may also include ulcers in the mouth, throat, nose, genitals and conjunctivitis (red and swollen eyes). The rash may progress to widespread blistering or peeling of the skin. If you have developed Stevens-Johnson Syndrome with the use of febuxostat, you must not be restarted on AGOUT at any time. If you developed a rash or these skin symptoms, seek immediate advice from a doctor and tell that you are taking this medicine. &bull; If you are having a gout attack at the moment (a sudden onset of severe pain, tenderness, redness, warmth and swelling in a joint), wait for the gout attack to subside before first starting treatment with Agout. For some people, gout attacks may flare up when starting certain medicines that control uric acid levels. Not everyone gets flares, but you could get a flare-up even if you are taking Agout, and especially during the first weeks or months of treatment. It is important to keep taking Agout even if you have a flare, as Agout is still working to lower uric acid. Over time, gout flares will occur less often and be less painful if you keep taking Agout every day. Your doctor will often prescribe other medicines, if they are needed, to help prevent or treat the symptoms of flares (such as pain and swelling in a joint). In patients with very high urate levels (e.g. those undergoing cancer chemotherapy), treatment with uric acid-lowering medicines could lead to the build-up of xanthine in the urinary tract, with possible stones, even though this has not been observed in patients being treated with febuxostat for Tumor Lysis Syndrome. Your doctor may ask you to have blood tests to check that your liver is working normally.</p><p><strong>Children and Adolescents</strong></p><p>Do not give the medicine to children under age of 18 because the safety and efficacy have no been established.</p><p><strong>Taking other medicines:</strong></p><p>Please tell your doctor or pharmacist if you are taking, or have recently taken, any other medicines, including medicines obtained without a prescription. It is especially important to tell your doctor or pharmacist if you are taking medicines containing any of the following substances as they may interact with Agout and your doctor may wish to consider necessary measures: &bull; Mercaptopurine (used to treat cancer). &bull; Azathioprine (used to reduce immune response). &bull; Theophylline (used to treat asthma).</p><p>&nbsp;</p><p><strong>Taking AGOUT with food and drink:</strong></p><p>The tablets should be taken by mouth and can be taken with or without food.</p><p><strong>Pregnancy and breast-feeding:</strong></p><p>It is not known if Febuxostat may harm your unborn child. Agout should not be used during pregnancy. It is not known if Febuxostat may pass into human breast milk. You should not use Agout if you are breast feeding, or if you are planning to breastfeed. If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p><strong>Driving and using machines</strong></p><p>you should be aware that you may experience dizziness, sleepiness, blurred vision and numbness or tingling sensation during treatment and should not drive or operate machines if affected.</p><p><strong>Important information about some of the ingredients of AGOUT:</strong></p><p>Agout tablets contain lactose (a type of sugar). If you have been told that you have intolerance to some sugars contact your doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. &bull; The usual dose is one tablet daily. &bull; The tablets should be taken by mouth and can be taken with or without food.</p><p><strong>Gout</strong></p><p>AGOUT Tablets are available as 40mg, 80mg tablet or a 120mg tablet. Your doctor will have prescribed the strength most suitable for you. Continue to take Febuxostat Tablets every day even when you are not experiencing gout flare or attack.</p><p><strong>Prevention and treatment of high uric acid levels in patients undergoing cancer chemotherapy</strong></p><p>AGOUT is available as a 120 mg tablet. Start taking AGOUT tablets two days before chemotherapy and continue its use according to your doctor&rsquo;s advice. Usually, treatment is short-term.</p><p><strong>If you take more AGOUT than you should:</strong></p><p>In the event of an accidental overdose ask your doctor what to do, or contact your nearest accident and emergency department.</p><p><strong>If you forget to take AGOUT:</strong></p><p>If you miss a dose of Agout take it as soon as you remember unless it is almost time for your next dose, in which case miss out the forgotten dose and take your next dose at the normal time. Do not take a double dose to make up for a forgotten dose.</p><p><strong>If you stop taking AGOUT:</strong></p><p>Do not stop taking Agout without the advice of your doctor even if you feel better. If you stop taking Agout your uric acid levels may begin to rise and your symptoms may worsen due to the formation of new crystals of urate in and around your joints and kidneys. If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Agout can cause side effects, although not everybody gets them.<strong> Stop taking this medicine and contact your doctor immediately or go to an emergency department nearby </strong>if the following rare (may affect up to 1 in 1,000 people) side effects occur, because a serious allergic reaction might follow: &bull; anaphylactic reactions, drug hypersensitivity (see also section 2 &ldquo;Warnings and precautions&rdquo;) &bull; potentially life-threatening skin rashes characterized by formation of blisters and shedding of the skin and inner surfaces of body cavities, eg. mouth and genitals, painful ulcers in the mouth and/or genital areas, accompanied by fever, sore throat and fatigue (StevensJohnson Syndrome/ Toxic Epidermal Necrolysis), or by enlarged lymph nodes, liver enlargement, hepatitis (up to liver failure), raising of the white-cells count in the blood (drug reaction with eosinophilia and systemic symptoms-DRESS) (see section 2). &bull; generalised skin rashes</p><p>&nbsp;</p><p><strong>Common side effects</strong> (reported in more than 1 in 100 patients but less than 1 in 10 patients) are:</p><p>&bull; Abnormal liver test results. &bull; Diarrhea. &bull; Headache. &bull; Rashes. &bull; Nausea. &bull; Increase in gout symptoms. &bull; Localized swelling due to retention of fluids in tissues (oedema)&nbsp;</p><p><strong>Uncommon side effects</strong> (more than 1 in 1,000 patients but less than 1 in 100 patients) are:</p><p>&bull; Decreased appetite, change in blood sugar levels (diabetes) of which a symptom may be excessive thirst, increased blood fat levels, weight increase &bull; Loss of sex drive &bull; Difficulty in sleeping, sleepiness &bull; Dizziness, numbness, tingling, reduced or altered sensation (hypoesthesia, hemiparesis or paraesthesia)&nbsp;&bull; Altered sense of taste, diminished sense of smell (hyposmia) &bull; Abnormal ECG heart tracing, irregular or rapid heartbeats, feeling your heart beat (palpitation) &bull; Hot flushes or flushing (e.g. Redness of the face or neck), increased blood pressure, bleeding (hemorrhage, seen only in patients taking chemotherapy for blood disorders) &bull; Cough, shortness of breath, chest discomfort or pain, inflammation of nasal passage and/or throat (upper respiratory tract infection), bronchitis &bull; Dry mouth, abdominal pain/discomfort or wind, heartburn/indigestion, constipation, more frequent passing of stools, vomiting, stomach discomfort &bull; Itching, hives, skin inflammation, skin discoloration, small red or purple spots on the skin, small flat red spots on the skin, flat red area on the skin that is covered with small confluent bumps, rash, areas of redness and spots on the skin, other types of skin conditions &bull; Muscle cramp, muscle weakness, pain/ache in muscles/joints, bursitis or arthritis (inflammation of joints usually accompanied by pain, swelling and/ or stiffness), pain in extremities, back pain, muscle spasm &bull; Blood in the urine, abnormal frequent urination, abnormal urine tests (increased level of proteins in the urine), a reduction in the ability of the kidneys to function properly &bull; Fatigue, chest pain, chest discomfort &bull; Stones in the gallbladder or in bile ducts (cholelithiasis) &bull; Increase in blood thyroid stimulating hormone (tsh) level &bull; Changes in blood chemistry or amount of blood cells or platelets (abnormal blood test results) &bull; Kidney stones &bull; Erectile difficulties.</p><p>&nbsp;</p><p><strong>Rare side effects</strong> (more than 1 in 10,000 patients but less than 1 in 1,000 patients) are:</p><p>&bull; Muscle damage, a condition which on rare occasions can be serious. It may cause muscle problems and particularly, if at the same time, you feel unwell or have a high temperature it may be caused by an abnormal muscle breakdown. Contact your doctor immediately if you experience muscle pain, tenderness or weakness &bull; Severe swelling of the deeper layers of the skin, especially around the lips, eyes, genitals, hands, feet or tongue, with possible sudden difficult breathing &bull; High fever in combination with measles-like skin rash, enlarged lymph nodes, liver enlargement, hepatitis (up to liver failure), raising of the white cells count in the blood (leukocytosis, with or without eosinophilia) &bull; Reddening of the skin (erythema), rash in various types (e.g. Itchy, with white spots, with blisters, with blisters containing pus, with shedding of the skin, measles-like rash), widespread erythema, necrosis, and bullous detachment of the epidermis and mucous membranes, resulting in exfoliation and possible sepsis (stevens-johnson syndrome/toxic epidermal necrolysis) &bull; Nervousness &bull; Feeling thirsty &bull; Ringing in the ears &bull; Blurred vision, change in vision &bull; Hair loss &bull; Mouth ulceration&nbsp;&bull; Inflammation of the pancreas: common symptoms are abdominal pain, nausea and vomiting &bull; Increased sweating &bull; Weight decrease, increased appetite, uncontrolled loss of appetite (anorexia) &bull; Muscle and/or joint stiffness &bull; Abnormally low blood cell counts (white or red blood cells or platelets) &bull; Urgent need to urinate &bull; Changes or decrease in urine amount due to inflammation in the kidneys (tubulointerstitial nephritis) &bull; Inflammation of the liver (hepatitis) &bull; Yellowing of the skin (jaundice) &bull; Liver damage &bull; Increased level of creatine phosphokinase in blood (an indicator of muscle damage) &bull; Sudden cardiac death. If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Store below 30oC. &bull; Keep this medicine out of the sight and reach of children. &bull; Do not use this medicine after the expiry date which is stated on the carton and the tablet blister foil after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month. &bull; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is Febuxostat. Each film coated tablet contains: 40 mg, 80 mg or 120 mg of Febuxostat. The other ingredients are: Tablet core: lactose fast flow, microcrystalline cellulose, magnesium stearate, hydroxypropylcellulose low-S, croscarmellose sodium, colloidal Silicon Dioxide. Film-coating: Opadry OY-37202 Dark Tan, Purified Water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Agout 40mg film-coated tablets are light brown to brown color, Oblong, biconvex, with "22"
debossed on one side and plain surface on the other.
Agout 80mg film-coated tablets are light brown to brown color, Oblong, biconvex, with "23"
debossed on one side and plain surface on the other.
Agout 120mg film-coated tablets are light brown to brown color, Oblong, biconvex, with "24"
debossed on one side and plain surface on the other.
Each pack of Agout contains 30 film-coated tablets (40mg- 2 blister strips; 80mg- 3 blister strips;
120mg- 3 blister strips) per unit carton.
Marketing Authorization Holder & Manufacturer 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>SPIMACO</p><p>Al-Qassim Pharmaceutical Plant</p><p>Saudi Arabia.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                 February 2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>تحتوي أقراص أجاوت علي المادة الفعالة )فيبوكسوستات( و التي تستعمل لعالج حاالت النقرس و هي حاالت تنجم عن حدوث زيادة في تركيز مادة كيميائية تدعى حمض اليوريك ) يورات( داخل جسم اإلنسان. وفي حالة بعض المرضى تصبح كمية حمض اليوريك في الدم مرتفعة جدا فتبدأ بالترسب. وعند ذلك تبدأ بلورت يورات بالتكون في كل من المفاصل والكلى وحولهما. هذه البلورات قد تسبب بشكل مفاجئ؛ حدوث ألم شديد، احمرار، سخونة وتورم في المفصل ) تدعى نوبة النقرس(. إن إهمال عالج هذه الحاالت يؤدي إلى تكون تراكمات كبيرة تدعى حصيبة ) توفي( في المفاصل وحولها. هذه الحصيبة قد تؤدي إلى التسبب بحدوث تلف في المفصل والعظم. أجاوت يعمل على تقليل مستوى تركيز حمض اليوريك في الدم. إن المحافظة على هذا المستوى المنخفض من تركيز حمض اليوريك باستخدام أجاوت مرة واحدة يوميا يمنع من تكون هذه البلورات ومع مرور الوقت تبدأ األعراض باالختفاء. كما أن المحافظة على مستوى تركيز حمض اليوريك منخفضا في الدم لفترة زمنية طويلة يؤدي أيضا إلى تقلص حجم الحصيبة. يستخدم أجاوت 120 ملجم أيضا لعالج ومنع ارتفاع مستويات حمض اليوريك في الدم الذي قد يحدث عند البدء في تلقي العالج الكيميائي لسرطان الدم. عندما يتم إعطاء العالج الكيميائي، ويتم تدمير الخاليا السرطانية، قد تزيد مستويات حمض اليوريك في الدم تبعا لذلك، ما لم يتم منع تكوين حمض اليوريك . أجاوت هو دواء للبالغين</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>موانع تناول أجاوت</strong></p><p>&nbsp;&bull; إذا كنت تعاني من فرط التحسس )التآق( من مادة فيبوكسوستات أو ألي من مكونات أجاوت األخرى.</p><p><strong>االحتياطات عند تناول أجاوت</strong></p><p>قم باستشارة طبيبك قبل البدء بتناول أجاوت إذا: &bull; كنت مصابا أو أصبت سابقا بقصور القلب أو بحدوث مشاكل في القلب (حيث انه في احدى الدراسات التي تمت على المرضى المصابين بأمراض قلبية كان هناك زيادة في خطورة الوفاة بمرض قلبي بدرجة اكبر من هؤالء الذين تناولو الوبيرينول على الرغم من ان نسبة حدوث اى مرض أو حدث قلبى خطير كان متساويا بين العالجين(.&bull; إذا كان لديك أو كنت تعاني من مرض كلوي و / أو رد فعل حساسية خطير اللوبيورينول )وهو دواء يستخدم لعالج النقرس (. &bull; إذا كان لديك أو كنت تعاني من مرض كبدي أو اضطرابات في اختبار وظائف الكبد. &bull; كنت قد خضعت سابقا للعالج من ارتفاع مستويات حمض اليوريك في الدم الناتج عن اإلصابة بالسرطان أو متالزمة ليش نيهان )مرض وراثي نادر الحدوث يتميز بارتفاع مستويات حمض اليوريك في الدم(. &bull; كنت تعاني من مشاكل في الغدة الدرقية. إذا حدث لك تجربة رد فعل حساسية تجاه أجاوت، توقف عن تناول هذا الدواء )انظر أيضا القسم 4 .)األعراض المحتملة من الحساسية قد تكون: &bull; الطفح الجلدي بما في ذلك أشكال حادة )مثل بثور أو عقيدات، حكة، طفح متقشر(، والحكة &bull; تورم في األطراف أو الوجه &bull; صعوبات في التنفس &bull; الحمى مع تضخم الغدد الليمفاوية &bull; ولكن أيضا حاالت حساسية خطيرة تهدد الحياة مع السكتة القلبية والدورة الدموية. قد يقرر الطبيب إلى إيقاف العالج بـ أجاوت بشكل دائم. كانت هناك تقارير نادرة من الطفح الجلدي مهددة للحياة )متالزمة ستيفنز جونسون( مع استخدام أجاوت، والتي تظهر في البداية كـ بقع محمرة تشبه الهدف أو البقع الدائرية في كثير من األحيان مع نقطة المركزية على الجذع. ويمكن أن تشمل أيضا تقرحات في الفم والحلق واألنف واألعضاء التناسلية والتهاب الملتحمة )عيون حمراء و منتفخة(. قد يتطور الطفح الجلدي إلى ظهور تقرحات أو تقشير الجلد على نطاق واسع. إذا حدثت لك متالزمة ستيفنز جونسون مع استخدام فيبوكسوستات، يجب أن ال تتناول أجاوت مرة أخري في أي وقت. إذا حدث لك طفح جلدي أو هذه األعراض الجلدية، اطلب المشورة الفورية من طبيب و قل له أنك تتناول هذا الدواء. &bull; كنت تتعرض حاليا لنوبة نقرس )نوبة مفاجئة من األلم الشديد، التشنج، االحمرار، السخونة، و تورم المفاصل( انتظر حتى تنتهي النوبة لديك قبل البدء بتناول أجاوت. في حالة بعض المرضى قد يصاحب البدء بتناول أدوية من مجموعة األدوية المخفضة لحمض اليوريك في الدم حدوث نوبات شديدة من النقرس )توهجات(. لكن ليس بالضرورة حدوث ذلك في حالة جميع المرضى. لذا قد يصاحب تناول أجاوت حدوث نوبات شديدة من النقرس )توهجات( خصوصا خالل األسابيع أواألشهراألولى من بدء العالج. من المهم جدا االستمرار في تناول أجاوت حتى لو تعرضت لمثل هذه النوبات عند تناول أجاوت. ألن أجاوت سيقوم بتخفيض مستوى حمض اليوريك لذلك مع مرور الوقت ستخف حدة نوبات النقرس كما سيقل معدل تكرارها في حالة استمرارك بتناول أجاوت. كما أن طبيبك سوف يقوم بوصف أدوية أخرى مع أجاوت إذا كنت بحاجة إلى ذلك لتخفيف أو منع ظهور أعراض نوبة النقرس ) مثل أعراض األلم وتورم المفصل(. في المرضى الذين يعانون من مستويات عالية جدًا من اليورات )مثل أولئك الذين يخضعون للعالج الكيميائي للسرطان( ، يمكن أن يؤدي العالج باألدوية الخافضة لحمض اليوريك إلى تراكم مادة الزانثين في المسالك البولية ، مع وجود حصوات محتملة ، على الرغم من عدم مالحظة ذلك في المرضى الذين يعالجون بالفيبوكسوستات لمتالزمة تحلل الورم. قد يطلب منك طبيبك القيام بفحص مستويات أنزيمات الكبد في الدم للتأكد من عمله بشكل طبيعي.</p><p><strong>األطفال والمراهقين</strong></p><p>ال تعطي الدواء لألطفال تحت سن 18 سنة ألنه لم يتم تأسيس السالمة والفعالية.</p><p><strong>التداخالت الدوائية من أخذ هذا الدواء مع أي أدوية أو أعشاب أو مكمالت غذائية</strong></p><p>فضال أخبر الطبيب أو الصيدلي إذا كنت تتناول أو قد تناولت مؤخرا أي دواء آخر يشمل ذلك األدوية التي تصرف بدون وصفة. تزداد أهمية ذلك بأن تخبر طبيبك أو الصيدلي ليقوم باإلجراء المناسب إذا كنت تتناول أي من األدوية التالية: &bull; ميركابتوبورين )يستخدم في عالج السرطان(. &bull; آزوثيوبرين )يستخدم كعالج لتقليل االستجابة المناعية(. &bull; ثيوفللين )يستخدم في عالج الربو(. إذ قد تحدث بعض التداخالت الدوائية وذلك عند تناول أجاوت بشكل متزامن مع هذه األدوية.</p><p><strong>تناول أجاوت مع الطعام والشراب</strong></p><p>يجب تناول أجاوت عن طريق الفم. ويكمن تناوله مع الطعام أو بدونه.</p><p><strong>الحمل والرضاعة</strong></p><p>من غير المعروف فيما إذا كانت مادة فيبوكسوستات تؤذي األجنة.</p><p>يجب عدم تناول أجاوت في حالة الحمل. من غير المعروف فيما إذا كان مادة فيبوكسوستات تفرز في حليب األم. يجب عدم تناول أجاوت في حالة اإلرضاع أو إذا كنت تخططين لإلرضاع. استشيري طبيبك على الفور إذا أصبحت حامال أو مرضعة، أو كنت تفكرين أو تخططين للحمل أثناء تناول أجاوت.</p><p><strong>تأثير أجاوت على القيادة واستعمال اآلالت</strong></p><p>يجب أن تدرك أنك قد تعاني من الدوار والنعاس وعدم وضوح الرؤية والتنميل أو اإلحساس بالوخز أثناء العالج ويجب أال تقود السيارة أو تشغل اآلالت إذا شعرت بذلك.</p><p><strong>معلومة هامة حول بعض مكونات أجاوت</strong></p><p>يحتوي أجاوت على الكتوز. استشر طبيبك قبل تناول هذا الدواء، إذا كان قد أخبرك سابقا بأنك تعاني من مشكلة عدم التحمل لبعض أنواع السكر.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>احرص دائ ًما على تناول هذا الدواء تما ًما كما أخبرك طبيبك. استشر طبيبك أو الصيدلي إذا لم تكن متأكدًا. . &bull; الجرعة المعتادة هي قرص واحد يومياً &bull; يجب تناول األقراص عن طريق الفم ويمكن تناولها مع الطعام أو بدونه.</p><p><strong>النقرس</strong></p><p>تتوافر أقراص أجاوت على هيئة أقراص 40 ملجم أو 80 ملجم أو 120 ملجم. سيصف طبيبك التركيز األنسب لك. استمر في تناول أقراص فيبوكسوستات كل يوم حتى عندما تكون ال تعاني من نوبة أو ألم النقرس.</p><p><strong>الوقاية والعالج من ارتفاع مستويات حمض اليوريك في المرضى الذين يخضعون للعالج الكيميائي للسرطان</strong></p><p>أجاوت متوفر كأقراص 120 مل جم. وفقً لنصيحة طبيبك. عادة ما يكون العالج ابدأ بتناول أقراص أجاوت قبل يومين من العالج الكيميائي واستمر في استخدامها ا قصير األمد.</p><p><strong>الجرعة الزائدة من أجاوت</strong></p><p>في حالة تناولك جرعة زائدة من أجاوت بالخطأ، اتصل بطبيبك أوإذهب إلى أقرب وحدة طوارئ في الحال.</p><p><strong>نسيان تناول جرعة من أجاوت</strong></p><p>في حالة نسيان جرعة من أجاوت تناول هذه الجرعة فور تذكرها إال إذا كان ذلك في وقت الجرعة التالية في هذه الحالة خذ الجرعة التالية فقط وأكمل كالمعتاد. ال تتناول جرعة مضاعفة لتعويض الجرعة التي نسيتها.</p><p><strong>التوقف عن تناول أجاوت</strong></p><p>ال تتوقف عن تناول أجاوت ما لم يطلب طبيبك منك ذلك حتى لو شعرت بالتحسن. إن التوقف عن تناول أجاوت قد يؤدي إلى ارتفاع مستويات حمض اليوريك لديك من جديد وبالتالي تبدأ األعراض بالظهور من جديد أو قد تزداد سوءا نتيجة لتكون بلورات يورات جديدة في كل من المفاصل والكلى وحولهما. إذا كانت لديك أية استفسارات إضافية حول هذا الدواء فضال استشر طبيبك أو الصيدلي.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>كما هو الحال في جميع األدوية، فإن تناول أجاوت قد يصاحبه ظهور بعض األعراض الجانبية والتي ليس بالضرورة أن تظهر عند كل من يتناول أجاوت. توقف عن تناول هذا الدواء واتصل بطبيبك فورا أو اذهب إلى قسم الطوارئ في مكان قريب إذا حدث أى من األعراض الجانبية النادرة )قد تؤثر على ما يصل إلى 1 في 1000 شخص(، ألن رد فعل تحسسي خطير قد يتبع ذلك: &bull; ردود فعل تحسسية، وفرط حساسية لألدوية )انظر أيضا القسم 2&quot; تحذيرات واحتياطات&quot;( &bull; الطفح الجلدي المهدد للحياة الذي يتميز بت كوين بثور وسفك الجلد واألسطح الداخلية للتجاويف الجسم، على سبيل المثال. الفم&nbsp;واألعضاء التناسلية وقرح مؤلمة في الفم و / أو المناطق التناسلية، يرافقه الحمى، والتهاب الحلق وتعب )متالزمة ستيفنز جونسون / انحالل البشرة السام(، أو عن طريق تضخم الغدد الليمفاوية، تضخم الكبد، والتهاب الكبد )إلى فشل الكبد(، زيادة عدد خاليا الدم البيضاء )رد فعل األدوية ب فرط الحمضات وأعراض DRESS النظامية( )انظر القسم 2.) &bull; الطفح الجلدي المعمم.</p><p><strong>أعراض جانبية شائعة</strong> ) سجل ظهورها بمعدل أكثر من حالة لكل مئة مريض ولكن أقل من حالة لكل عشرة مرضى(:</p><p>&bull; تغيرات في نتائج قيم اختبارات وظائف الكبد في الدم. &bull; اإلسهال. &bull; الصداع. &bull; طفح جلدي. &bull; الغثيان. &bull; زيادة في ظهور أعراض النقرس. &bull; تورم موضعي بسبب احتباس السوائل في األنسجة )وذمة(.</p><p><strong>أعراض جانبية غير شائعة</strong> ) سجل ظهورها بمعدل أكثر من حالة لكل ألف مريض ولكن أقل من حالة لكل مئة مريض(:</p><p>&bull; قلة الشهية ، تغير في مستويات السكر في الدم )داء السكري( والذي قد يكون من أعراضه العطش الشديد ، زيادة مستويات الدهون في الدم ، زيادة الوزن. &bull; فقدان الرغبة الجنسية. &bull; صعوبة النوم والنعاس &bull; الدوخة ، التنميل ، الوخز ، انخفاض أو تغير اإلحساس ) نقص الحس ، شلل نصفي أو تنميل( &bull; تغير في حاسة التذوق ، تضاؤل حاسة الشم )نقص الشم( &bull; تخطيط القلب غير الطبيعي ، عدم انتظام ضربات القلب أو تسارعها ، الشعور بضربات قلبك )خفقان( &bull; الهبات الساخنة أو االحمرار )مثل احمرار الوجه أو الرقبة( ، ارتفاع ضغط الدم ، النزيف )نزيف ، يظهر فقط في المرضى الذين يتناولون العالج الكيميائي الضطرابات الدم( &bull; السعال ، وضيق التنفس ، وانزعاج أو ألم في الصدر ، والتهاب الممرات األنفية و / أو الحلق )عدوى الجهاز التنفسي العلوي( ، والتهاب الشعب الهوائية &bull; جفاف الفم ، ألم في البطن / عدم راحة أو ريح ، حرقة في المعدة / عسر هضم ، إمساك ، خروج متكرر للبراز ، قيء ، انزعاج في المعدة &bull; الحكة ، والشرى ، والتهاب الجلد ، وتغير لون الجلد ، وبقع صغيرة حمراء أو أرجوانية على الجلد ، وبقع حمراء صغيرة مسطحة على الجلد ، ومنطقة حمراء مسطحة على الجلد مغطاة بنتوءات صغيرة متجمعة ، وطفح جلدي ، ومناطق احمرار وبقع على الجلد وأنواع أخرى من األمراض الجلدية &bull; تقلصات العضالت ، ضعف العضالت ، ألم / وجع في العضالت / المفاصل ، التهاب كيسي أو التهاب المفاصل )التهاب المفاصل عادة ما يكون مصحوبًا بألم ، وتورم و / أو تصلب( ، وآالم في األطراف ، وآالم في الظهر ، وتشنج عضلي &bull; دم في البول ، كثرة التبول غير الطبيعي ، اختبارات بول غير الطبيعية )زيادة مستوى البروتينات في البول( ، انخفاض في قدرة الكلى على العمل بشكل صحيح &bull; إرهاق وألم في الصدر وانزعاج في الصدر &bull; حصوات في المرارة أو القنوات الصفراوية )تحص صفراوي( &bull; زيادة مستوى هرمون الغدة الدرقية في الدم &bull; تغييرات في كيمياء الدم أو كمية خاليا الدم أو الصفائح الدموية )نتائج غير طبيعية لفحص الدم( &bull; حصى الكلى &bull; صعوبات االنتصاب</p><p><strong>عراض جانبية نادرة </strong>) سجل ظهورها بمعدل أكثر من حالة لكل 000,10 مريض ولكن أقل من حالة لكل ألف مريض(:</p><p>&bull; تلف العضالت ، وهي حالة يمكن أن تكون خطيرة في حاالت نادرة. يمكن أن تسبب مشاكل في العضالت وخاصة إذا شعرت في نفس الوقت بتوعك أو ارتفاع في درجة الحرارة فقد يكون نات ًجا عن انهيار عضلي غير طبيعي. اتصل بطبيبك على الفور إذا كنت تعاني من آالم أو ضعف في العضالت.</p><p>&bull; تورم شديد في الطبقات العميقة من الجلد ، خاصة حول الشفاه أو العينين أو األعضاء التناسلية أو اليدين أو القدمين أو اللسان ، مع احتمال صعوبة التنفس المفاجئ &bull; ارتفاع في درجة الحرارة مصحوبًا بطفح جلدي شبيه بالحصبة ، وتضخم في الغدد الليمفاوية ، وتضخم الكبد ، والتهاب الكبد )حتى فشل الكبد( ، وزيادة عدد الكريات البيضاء في الدم )زيادة عدد الكريات البيضاء ، مع فرط الحمضات أو بدونه( &bull; احمرار الجلد )الحمامي( ، والطفح الجلدي بأنواع مختلفة )على سبيل المثال ، حكة ، مع بقع بيضاء ، مع بثور ، مع بثور تحتوي على صديد ، مع تساقط الجلد ، طفح جلدي يشبه الحصبة( ، حمامي منتشر ، نخر ، وانفصال فقاعي من البشرة واألغشية المخاطية ، مما يؤدي إلى تقشير وإنتان محتمل )متالزمة ستيفنز جونسون / انحالل البشرة السمي النخري( &bull; العصبية &bull; الشعور بالعطش &bull; طنين في األذنين &bull; عدم وضوح الرؤية ، تغير في الرؤية &bull; تساقط الشعر &bull; تقرح الفم &bull; التهاب البنكرياس: األعراض الشائعة هي آالم البطن والغثيان والقيء &bull; زيادة التعرق &bull; انخفاض الوزن ، وزيادة الشهية ، وفقدان الشهية الالرادي &bull; تصلب العضالت و / أو المفاصل &bull; انخفاض غير طبيعي في عدد خاليا الدم )خاليا الدم البيضاء أو الحمراء أو الصفائح الدموية( &bull; الحاجة الملحة للتبول &bull; تغيرات أو نقصان في كمية البول بسبب التهاب الكلى )التهاب الكلية الخاللي( &bull; التهاب الكبد &bull; اصفرار الجلد )اليرقان( &bull; تلف الكبد &bull; زيادة مستوى فوسفوكيناز الكرياتين في الدم )مؤشر على تلف العضالت( &bull; الموت القلبي المفاجئ.</p><p>إذا ازدادت شدة إحدى هذه األعراض، أو أصبت بأية أعراض جانبية أخرى لم تذكر في هذه النشرة، أخبر طبيبك المعالج أو الصيدلي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull; يحفظ في درجة حرارة أقل من 30 درجة مئوية. &bull; يحفظ بعيدًا عن متناول ونظراألطفال. &bull; ال تستخدم هذا الدواء بعد تاريخ انتهاء الصالحية المذكور على العلبة أوالشريط بعد كلمة &quot;EXP .&quot;يشير تاريخ انتهاء الصالحية إلى اليوم األخير من ذلك الشهر. &bull; ال يجب التخلص من األدوية في مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من األدوية التي لم تعد تستخدمها. هذه التدابير سوف تساعد في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة: فيبوكسوستات. كل قرص مغلف بطبقة رقيقة يحتوي على 40 ملجم، 80 ملجم، 120 ملجم فيبوكسوستات. المكونات األخرى: لب القرص:الكتوز، ميكروكريستالين سيليلوز، ستيرات المغنيسيوم، هيدروكسي بروبيل سيليلوز، كروسكورمالوز الصوديوم، ثنائي أوكسيد السيليكون الغرواني. قشرة القرص: أوبادري 37202-OY صبغة غامقة، ماء نقي.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>إن أجاوت 40 متوافر على شكل أقراص مغلفة بطبقة رقيقة ذات شكل مستطيل محدب الوجهين لونها يتراوح بين اللون البني الفاتح والبني، منقوش على احدي جانبيها رقم &quot;22 &quot;وجلية السطح على الجانب اآلخر. إن أجاوت 80 متوافر على شكل أقراص مغلفة بطبقة رقيقة ذات شكل مستطيل محدب الوجهين لونها يتراوح بين اللون البني الفاتح والبني، منقوش على احدي جانبيها رقم &quot;23 &quot;وجلية السطح على الجانب اآلخر. إن أجاوت 120 متوافر على شكل أقراص مغلفة بطبقة رقيقة ذات شكل مستطيل محدب الوجهين لونها يتراوح بين اللون البني الفاتح والبني، منقوش على احدي جانبيها رقم &quot;24 &quot;وجلية السطح على الجانب اآلخر. كل عبوة تحتوى على 30 قرص مغلف بطبقة رقيقة )40 ملجم &ndash; شريطين ، 80 ملجم &ndash; 3 شرائط ، 120 ملجم 3</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>الدوائية</p><p>مصنع األدوية بالقصيم</p><p>المملكة العربية السعودية&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            فبراير 2021 .
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Agout 40
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Agout 40 mg tablet: Each tablet contains 40 mg of febuxostat. .
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Agout is indicated for the treatment of chronic hyperuricaemia in conditions where urate deposition has already occurred (including a history, or presence of, tophus and/or gouty arthritis). Febuxostat Tablets is indicated in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>Gout: The recommended oral dose of Febuxostat is 40 or 80 mg once daily without regard to food. If serum uric acid is &gt; 6 mg/dL (357 &mu;mol/L) after 2-4 weeks, Febuxostat 120 mg once daily may be considered.</p><p>Febuxostat Tablets works sufficiently quickly to allow retesting of the serum uric acid after 2 weeks. The therapeutic target is to decrease and maintain serum uric acid below 6 mg/dL (357 &mu;mol/L). Gout flare prophylaxis of at least 6 months is recommended (see section 4.4).</p><p><em>Elderly</em></p><p>No dose adjustment is required in the elderly (see section 5.2).</p><p><em>Renal impairment</em></p><p>The efficacy and safety have not been fully evaluated in patients with severe renal impairment (creatinine clearance &lt; 30 mL/min, see section 5.2). No dose adjustment is necessary in patients with mild or moderate renal impairment.</p><p><em>Hepatic impairment</em></p><p>The efficacy and safety of febuxostat have not been studied in patients with severe hepatic impairment (Child-Pugh Class C).</p><p>Gout: The recommended dose in patients with mild hepatic impairment is 80 mg. Limited information is available in patients with moderate hepatic impairment.</p><p><em>Paediatric population</em></p><p>The safety and the efficacy of Febuxostat Tablets in children aged below the age of 18 years have not been established. No data are available.</p><p><u>Method of administration</u></p><p>Oral use Febuxostat Tablets should be taken by mouth and can be taken with or without food.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
See also section 4.8.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Cardio-vascular disorders</u></p><p><u>Treatment of chronic hyperuricaemia</u></p><p>Treatment with febuxostat in patients with pre-existing major cardiovascular diseases (e.g. myocardial infarction, stroke or unstable angina) should be avoided, unless no other therapy options are appropriate. A numerical greater incidence of investigator-reported cardiovascular APTC events (defined endpoints from the Anti-Platelet Trialists&#39; Collaboration (APTC) including cardiovascular death, non-fatal myocardial infarction, non-fatal stroke) was observed in the febuxostat total group compared to the allopurinol group in the APEX and FACT studies (1.3 vs. 0.3 events per 100 Patient Years (PYs)), but not in the CONFIRMS study (see section 5.1 for detailed characteristics of the studies). The incidence of investigator-reported cardiovascular APTC events in the combined Phase 3 studies (APEX, FACT and CONFIRMS studies) was 0.7 vs. 0.6 events per 100 PYs. In the long-term extension studies the incidences of investigator-reported APTC events were 1.2 and 0.6 events per 100 PYs for febuxostat and allopurinol, respectively. No statistically significant differences were found and no causal relationship with febuxostat was established. Identified risk factors among these patients were a medical history of atherosclerotic disease and/or myocardial infarction, or of congestive heart failure.</p><p>&nbsp;</p><p><u>In the post registrational CARES trial (see section 5.1 for detailed characteristics of the study) the rate of MACE events was similar in febuxostat versus allopurinol treated patients (HR 1.03; 95% CI 0.87-1.23), but a higher rate of cardiovascular deaths was observed (4.3% vs. 3.2% of patients; HR 1.34; (95% CI 1.03-1.73). </u></p><p><u>Medicinal product allergy / hypersensitivity</u></p><p>Rare reports of serious allergic/hypersensitivity reactions, including life-threatening Stevens-Johnson Syndrome, Toxic epidermal necrolysis and acute anaphylactic reaction/shock, have been collected in the post-marketing experience. In most cases, these reactions occurred during the first month of therapy with febuxostat. Some, but not all of these patients reported renal impairment and/or previous hypersensitivity to allopurinol. Severe hypersensitivity reactions, including Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) were associated with fever, haematological, renal or hepatic involvement in some cases. Patients should be advised of the signs and symptoms and monitored closely for symptoms of allergic/hypersensitivity reactions (see section 4.8). Febuxostat treatment should be immediately stopped if serious allergic/hypersensitivity reactions, including Stevens-Johnson Syndrome, occur since early withdrawal is associated with a better prognosis. If patient has developed allergic/ hypersensitivity reactions including Stevens-Johnson Syndrome and acute anaphylactic reaction/ shock, febuxostat must not be re-started in this patient at any time.</p><p><u>Acute gouty attacks (gout flare)</u></p><p>Febuxostat treatment should not be started until an acute attack of gout has completely subsided. Gout flares may occur during initiation of treatment due to changing serum uric acid levels resulting in mobilization of urate from tissue deposits (see section 4.8 and 5.1). At treatment initiation with febuxostat flare prophylaxis for at least 6 months with an NSAID or colchicine is recommended (see section 4.2). If a gout flare occurs during febuxostat treatment, it should not be discontinued. The gout flare should be managed concurrently as appropriate for the individual patient. Continuous treatment with febuxostat decreases frequency and intensity of gout flares.</p><p><u>Xanthine deposition</u></p><p>In patients in whom the rate of urate formation is greatly increased (e.g. malignant disease and its treatment, Lesch-Nyhan syndrome) the absolute concentration of xanthine in urine, could in rare cases,rise sufficiently to allow deposition in the urinary tract. As there has been no experience with febuxostat, its use in patients with Lesch-Nyhan Syndrome is not recommended.</p><p><u>Mercaptopurine/azathioprine</u></p><p>Febuxostat use is not recommended in patients concomitantly treated with mercaptopurine/azathioprine as inhibition of xanthine oxidase by febuxostat may cause increased plasma concentrations of mercaptopurine/azathioprine that could result in severe toxicity. No interaction studies have been performed in humans. Where the combination cannot be avoided, a reduction of the dose of mercaptopurine/azathioprine is recommended. Based on modelling and simulation analysis of data from a pre-clinical study in rats, when coadministered with febuxostat, the dose of mercaptopurine/azathioprine should be reduced to the 20 % or less of the previously prescribed dose in order to avoid possible haematological effects (see sections 4.5 and 5.3). The patients should be closely monitored and the dose of mercaptopurine/azathioprine should be subsequently adjusted based on the evaluation of the therapeutic response and the onset of eventual toxic effects.</p><p><u>Organ transplant recipients</u></p><p>As there has been no experience in organ transplant recipients, the use of febuxostat in such patients is not recommended (see section 5.1).</p><p><u>Theophylline</u></p><p>Co-administration of febuxostat 80 mg and theophylline 400 mg single dose in healthy subjects showed absence of any pharmacokinetic interaction (see section 4.5). Febuxostat 80 mg can be used in patients concomitantly treated with theophylline without risk of increasing theophylline plasma levels. No data is available for febuxostat 120 mg.</p><p><u>Liver disorders</u></p><p>During the combined phase 3 clinical studies, mild liver function test abnormalities were observed in patients treated with febuxostat (5.0 %). Liver function test is recommended prior to the initiation of therapy with febuxostat and periodically thereafter based on clinical judgment (see section 5.1)</p><p><u>Thyroid disorders</u></p><p>Increased TSH values (&gt; 5.5 &mu;IU/mL) were observed in patients on long-term treatment with febuxostat (5.5 %) in the long term open label extension studies. Caution is required when febuxostat is used in patients with alteration of thyroid function (see section 5.1).</p><p><u>Lactose</u></p><p>Febuxostat Tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.</p><p><u>Sodium</u></p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &#39;sodium-free&#39;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Mercaptopurine/azathioprine</u></p><p>On the basis of the mechanism of action of febuxostat on XO inhibition concomitant use is not recommended. Inhibition of XO by febuxostat may cause increased plasma concentrations of these medicinal products leading to toxicity. Drug interaction studies of febuxostat with medicinal products (except theophylline) that are metabolized by XO have not been performed in humans.</p><p>Modelling and simulation analysis of data from a pre-clinical study in rats indicates that, in case of concomitant administration with febuxostat, the dose of mercaptopurine/azathioprine should be reduced to 20 % or less of the previously prescribed dose (see sections 4.4 and 5.3). Drug interaction studies of febuxostat with other cytotoxic chemotherapy have not been conducted.</p><p><u>Rosiglitazone/CYP2C8 substrates</u></p><p>Febuxostat was shown to be a weak inhibitor of CYP2C8 in vitro. In a study in healthy subjects, coadministration of 120 mg febuxostat QD with a single 4 mg oral dose of rosiglitazone had no effect on the pharmacokinetics of rosiglitazone and its metabolite N-desmethyl rosiglitazone, indicating that febuxostat is not a CYP2C8 enzyme inhibitor in vivo. Thus, co-administration of febuxostat with rosiglitazone or other CYP2C8 substrates is not expected to require any dose adjustment for those compounds.</p><p><u>Theophylline</u></p><p>An interaction study in healthy subjects has been performed with febuxostat to evaluate whether the inhibition of XO may cause an increase in the theophylline circulating levels as reported with other XO inhibitors. The results of the study showed that the co-administration of febuxostat 80 mg QD with theophylline 400 mg single dose has no effect on the pharmacokinetics or safety of theophylline.Therefore no special caution is advised when febuxostat 80 mg and theophylline are given concomitantly. No data is available for febuxostat 120 mg.</p><p><u>Naproxen and other inhibitors of glucuronidation</u></p><p>Febuxostat metabolism depends on Uridine Glucuronosyl Transferase (UGT) enzymes. Medicinal products that inhibit glucuronidation, such as NSAIDs and probenecid, could in theory affect the elimination of febuxostat. In healthy subjects concomitant use of febuxostat and naproxen 250 mg twice daily was associated with an increase in febuxostat exposure (Cmax 28 %, AUC 41 % and t1/2 26 %). In clinical studies the use of naproxen or other NSAIDs/Cox-2 inhibitors was not related to any clinically significant increase in adverse events. Febuxostat can be co-administered with naproxen with no dose adjustment of febuxostat or naproxen being necessary</p><p><u>Inducers of glucuronidation</u></p><p>Potent inducers of UGT enzymes might possibly lead to increased metabolism and decreased efficacy of febuxostat. Monitoring of serum uric acid is therefore recommended 1-2 weeks after start of treatment with a potent inducer of glucuronidation. Conversely, cessation of treatment of an inducer might lead to increased plasma levels of febuxostat.</p><p><u>Colchicine/indometacin/hydrochlorothiazide/warfarin</u></p><p>Febuxostat can be co-administered with colchicine or indomethacin with no dose adjustment of febuxostat or the co-administered active substance being necessary. No dose adjustment is necessary for febuxostat when administered with hydrochlorothiazide. No dose adjustment is necessary for warfarin when administered with febuxostat. Administration of febuxostat (80 mg or 120 mg once daily) with warfarin had no effect on the pharmacokinetics of warfarin in healthy subjects. INR and Factor VII activity were also not affected by the co-administration of febuxostat.</p><p><u>Desipramine/CYP2D6 substrates</u></p><p>Febuxostat was shown to be a weak inhibitor of CYP2D6 in vitro. In a study in healthy subjects, 120 mg febuxostat QD resulted in a mean 22 % increase in AUC of desipramine, a CYP2D6 substrate indicating a potential weak inhibitory effect of febuxostat on the CYP2D6 enzyme in vivo. Thus, co-administration of febuxostat with other CYP2D6 substrates is not expected to require any dose adjustment for those compounds.</p><p><u>Antacids</u></p><p>Concomitant ingestion of an antacid containing magnesium hydroxide and aluminium hydroxide has been shown to delay absorption of febuxostat (approximately 1 hour) and to cause a 32 % decrease in Cmax, but no significant change in AUC was observed. Therefore, febuxostat may be taken without regard to antacid use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>Data on a very limited number of exposed pregnancies have not indicated any adverse effects of febuxostat on pregnancy or on the health of the foetus/new born child. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development or parturition (see section 5.3). The potential risk for human is unknown. Febuxostat Tablets should not be used during pregnancy.</p><p><u>Breast-feeding</u></p><p>It is unknown whether febuxostat is excreted in human breast milk. Animal studies have shown excretion of this active substance in breast milk and an impaired development of suckling pups. A risk to a suckling infant cannot be excluded. Febuxostat Tablets should not be used while breast-feeding.</p><p><u>Fertility</u></p><p>In animals, reproduction studies up to 48 mg/kg/day showed no dose-dependent adverse effects on fertility (see section 5.3). The effect of febuxostat on human fertility is unknown.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Somnolence, dizziness, paraesthesia and blurred vision have been reported with the use of febuxostat. Patients should exercise caution before driving, using machinery or participating in dangerous activities until they are reasonably certain that Febuxostat Tablets does not adversely affect performance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Summary of the safety profile</em></p><p>The most commonly reported adverse reactions in clinical trials (4,072 subjects treated at least with a dose from 10 mg to 300 mg) and post-marketing experience in gout patients are gout flares, liver function abnormalities, diarrhoea, nausea, headache, rash and oedema. These adverse reactions were mostly mild or moderate in severity. Rare serious hypersensitivity reactions to febuxostat, some of which were associated to systemic symptoms, and rare events of sudden cardiac death, have occurred in the postmarketing experience.</p><p><em>Tabulated list of adverse reactions</em></p><p>Common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100) and rare (&ge; 1/10,000 to &lt; 1/1,000) adverse reactions occurring in patients treated with febuxostat are listed below. The frequencies are based on studies and post-marketing experience in gout patients. Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p><strong>Table 1: Adverse reactions in combined pha</strong><strong>se 3, long-term extension studies and post-marketing experience in gout patients</strong></p><p>&nbsp;</p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td>Blood and lymphatic system disorders</td><td><p>Rare</p><p>Pancytopenia, thrombocytopenia, agranulocytosis*</p></td></tr><tr><td>Immune system disorders</td><td><p>Rare</p><p>Anaphylactic reaction* , drug hypersensitivity</p></td></tr><tr><td>Endocrine disorders&nbsp;</td><td><p>Uncommon</p><p>Blood thyroid stimulating hormone increased</p></td></tr><tr><td>Eye disorders&nbsp;</td><td><p>Rare</p><p>Blurred vision</p></td></tr><tr><td>Metabolism and nutrition disorders</td><td><p>Common***</p><p>Gout flares</p><p>Uncommon</p><p>Diabetes mellitus, hyperlipidemia, decrease appetite, weight increase</p><p>Rare</p><p>Weight decrease, increase appetite, anorexia</p></td></tr><tr><td>Psychiatric disorders</td><td><p>Uncommon</p><p>Libido decreased, insomnia</p><p>Rare</p><p>Nervousness</p></td></tr><tr><td>Nervous system disorders&nbsp;</td><td><p>Common</p><p>Headache</p><p>Uncommon</p><p>Dizziness, paraesthesia, hemiparesis, somnolence, altered taste, hypoaesthesia, hyposmia</p></td></tr><tr><td>Ear and labyrinth disorders&nbsp;</td><td><p>Rare</p><p>Tinnitus</p></td></tr><tr><td>Cardiac disorders</td><td><p>Uncommon</p><p>Atrial fibrillation, palpitations, ECG abnormal</p><p>Rare</p><p>Sudden cardiac death*</p></td></tr><tr><td>Vascular disorders&nbsp;</td><td><p>Uncommon</p><p>Hypertension, flushing, hot flush</p></td></tr><tr><td>Respiratory, thoracic and mediastinal disorders</td><td><p>Uncommon</p><p>Dyspnoea, bronchitis, upper respiratory tract infection, cough</p></td></tr><tr><td>Gastrointestinal disorders</td><td><p>Common</p><p>Diarrhoea**, nausea</p><p>Uncommon</p><p>Abdominal pain, abdominal distension, gastro-oesophageal reflux disease, vomiting, dry mouth, dyspepsia, constipation, frequent stools, flatulence, gastrointestinal discomfort</p><p>Rare</p><p>Pancreatitis, mouth ulceration</p></td></tr><tr><td>Hepatobiliary disorders</td><td><p>Common</p><p>Liver function abnormalities**</p><p>Uncommon</p><p>Cholelithiasis</p><p>Rare</p><p>Hepatitis, jaundice* , liver injury*</p></td></tr><tr><td>Skin and subcutaneous tissue disorders</td><td><p>Common</p><p>Rash (including various types of rash reported with lower frequencies, see below)</p><p>Uncommon</p><p>Dermatitis, urticaria, pruritus, skin discolouration, skin lesion, petechiae, rash macular, rash maculopapular, rash papular</p><p>Rare</p><p>Toxic epidermal necrolysis* , Stevens-Johnson Syndrome* , angioedema* , drug reaction with eosinophilia and systemic&nbsp;symptoms* , generalized rash (serious)* , erythema, exfoliative rash, rash follicular, rash vesicular, rash pustular, rash pruritic* , rash erythematous, rash morbillifom, alopecia, hyperhidrosis</p></td></tr><tr><td>Musculoskeletal and connective tissue disorders</td><td><p>Uncommon</p><p>Arthralgia, arthritis, myalgia, musculoskeletal pain, muscle weakness, muscle spasm, muscle tightness, bursitis</p><p>Rare</p><p>Rhabdomyolysis* , joint stiffness, musculoskeletal stiffness</p></td></tr><tr><td>Renal and urinary disorders</td><td><p>Uncommon</p><p>Renal failure, nephrolithiasis, haematuria, pollakiuria, proteinuria</p><p>Rare</p><p>Tubulointerstitial nephritis* , micturition urgency</p></td></tr><tr><td>Reproductive system and breast disorders&nbsp;</td><td><p>Uncommon</p><p>Erectile dysfunction</p></td></tr><tr><td>General disorders and administration site conditions</td><td><p>Common</p><p>Oedema</p><p>Uncommon</p><p>Fatigue, chest pain, chest discomfort</p><p>Rare</p><p>Thirst</p></td></tr><tr><td>Investigations</td><td><p>Uncommon</p><p>Blood amylase increase, platelet count decrease, WBC decrease, lymphocyte count decrease, blood creatine increase, blood creatinine increase, haemoglobin decrease, blood urea increase, blood triglycerides increase, blood cholesterol increase, haematocritic decrease, blood lactate dehydrogenase increased, blood potassium increase</p><p>Rare</p><p>Blood glucose increase, activated partial thromboplastin time prolonged, red blood cell count decrease, blood alkaline phosphatase increase, blood creatine phosphokinase increase*</p></td></tr></tbody></table><p>* Adverse reactions coming from post-marketing experience</p><p>** Treatment-emergent non-infective diarrhoea and abnormal liver function tests in the combined Phase 3 studies are more frequent in patients concomitantly treated with colchicine.</p><p>*** See section 5.1 for incidences of gout flares in the individual Phase 3 randomized controlled studies.</p><p><em>Description of selected adverse reactions</em></p><p>Rare serious hypersensitivity reactions to febuxostat, including Stevens-Johnson Syndrome, Toxic epidermal necrolysis and anaphylactic reaction/shock, have occurred in the post-marketing experience. Stevens-Johnson Syndrome and Toxic epidermal necrolysis are characterised by progressive skin rashes associated with blisters or mucosal lesions and eye irritation. Hypersensitivity reactions to febuxostat can be associated to the following symptoms: skin reactions characterised by infiltrated maculopapular eruption, generalised or exfoliative rashes, but also skin lesions, facial oedema, fever, haematologic abnormalities such as thrombocytopenia and eosinophilia, and single or multiple organ involvement (liver and kidney including tubulointerstitial nephritis) (see section 4.4).</p><p>Gout flares were commonly observed soon after the start of treatment and during the first months. Thereafter, the frequency of gout flare decreases in a time-dependent manner. Gout flare prophylaxis is recommended (see section 4.2 and 4.4).</p><p><u>Reporting of suspected adverse reactions</u></p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td><p>For Saudi Arabia:</p><p>&bull; The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>&bull; Fax: +966-11-205-7662</p><p>&bull; Call NPC at +966-11-2038222, Exts: 2317-2356-2340.</p><p>&bull; Reporting hotline: 19999.</p><p>&bull; E-mail: npc.drug@sfda.gov.sa</p><p>&bull; Website: https://ade.sfda.gov.sa</p></td></tr><tr><td><p>For UAE</p><p>&bull; Pharmacovigilance &amp; Medical Device section P.O.Box: 1853</p><p>  &bull; Tel: 80011111</p><p>&bull; Email: pv@moh.gov.ae</p><p>&bull; Drug Department Ministry of Health &amp; Prevention Dubai</p></td></tr><tr><td><p>For Oman</p><p>&bull; Department of Pharmacovigilance &amp; Drug Information</p><p>&bull; Directorate General of Pharmaceutical Affairs &amp; Drug Control</p><p>&bull; Ministry of Health, Sultanate of Oman</p><p>&bull; Phone Nos. 22357687 / 22357686</p><p>&bull; Fax: 22358489</p><p>&bull; Email: dg-padc@moh.gov.om</p><p>&bull; Website: www.moh.gov.om</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients with an overdose should be managed by symptomatic and supportive care.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;Pharmacotherapeutic group: Antigout preparation, preparations inhibiting uric acid production</p><p>ATC code: M04AA03</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Uric acid is the end product of purine metabolism in humans and is generated in the cascade of hypoxanthine &rarr; xanthine &rarr; uric acid. Both steps in the above transformations are catalyzed by xanthine oxidase (XO). Febuxostat is a 2-arylthiazole derivative that achieves its therapeutic effect of decreasing serum uric acid by selectively inhibiting XO. Febuxostat is a potent, non-purine selective inhibitor of XO (NP-SIXO) with an in vitro inhibition Ki value less than 1 nanomolar. Febuxostat has been shown to potently inhibit both the oxidized and reduced forms of XO. At therapeutic concentrations febuxostat does not inhibit other enzymes involved in purine or pyrimidine metabolism, namely, guanine deaminase, hypoxanthine guanine phosphoribosyltransferase, orotate phosphoribosyltransferase, orotidine monophosphate decarboxylase or purine nucleoside phosphorylase.</p><p><u>Clinical efficacy and safety</u></p><p><u>Gout</u></p><p>The efficacy of febuxostat was demonstrated in three Phase 3 pivotal studies (the two pivotal APEX and FACT studies, and the additional CONFIRMS study described below) that were conducted in 4,101 patients with hyperuricaemia and gout. In each phase 3 pivotal study, febuxostat demonstrated superior ability to lower and maintain serum uric acid levels compared to allopurinol. The primary efficacy endpoint in the APEX and FACT studies was the proportion of patients whose last 3 monthly serum uric acid levels were &lt; 6.0 mg/dL (357 &mu;mol/L). In the additional phase 3 CONFIRMS study, for which results became available after the marketing authorisation for febuxostat was first issued, the primary efficacy endpoint was the proportion of patients whose serum urate level was &lt; 6.0 mg/dL at the final visit. No patients with organ transplant have been included in these studies (see section 4.2). APEX Study: The Allopurinol and Placebo-Controlled Efficacy Study of Febuxostat (APEX) was a Phase 3, randomized, double-blind, multicenter, 28-week study. One thousand and seventy-two (1,072) patients were randomized: placebo (n=134), febuxostat 80 mg QD (n=267), febuxostat 120 mg QD (n=269), febuxostat 240 mg QD (n=134) or allopurinol (300 mg QD [n=258] for patients with a baseline serum creatinine &le; 1.5 mg/dL or 100 mg QD [n=10] for patients with a baseline serum creatinine &gt; 1.5 mg/dL and &le; 2.0 mg/dL). 240 mg febuxostat (2 times the recommended highest dose) was used as a safety evaluation dose. The APEX study showed statistically significant superiority of both the febuxostat 80 mg QD and the febuxostat 120 mg QD treatment arms versus the conventionally used doses of allopurinol 300 mg (n = 258) / 100 mg (n = 10) treatment arm in reducing the sUA below 6 mg/dL (357 &mu;mol/L) (see Table 2 and Figure 1). FACT Study: The Febuxostat Allopurinol Controlled Trial (FACT) Study was a Phase 3, randomized, double-blind, multicenter, 52-week study. Seven hundred sixty (760) patients were randomized: febuxostat 80 mg QD (n=256), febuxostat 120 mg QD (n=251), or allopurinol 300 mg QD (n=253). The FACT study showed the statistically significant superiority of both febuxostat 80 mg and febuxostat 120 mg QD treatment arms versus the conventionally used dose of allopurinol 300 mg treatment arm in reducing and maintaining sUA below 6 mg/dL (357 &mu;mol/L). Table 2 summarises the primary efficacy endpoint results:</p><p><strong>Table 2 </strong></p><p><strong>Proportion of Patients with Serum Uric Acid Levels &lt; 6.0 mg/dL (357 &mu;mol/L)</strong></p><p><strong>Last Three Monthly Visits</strong></p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td>Study</td><td>Febuxostat 80 mg QD</td><td>Febuxostat 120 mg QD</td><td>Allopurinol 300 / 100 mg QD1</td></tr><tr><td>APEX (28 weeks)</td><td>48 %* (n=262)</td><td>65 % *, # (n=269)</td><td>22 % (n=268)</td></tr><tr><td>FACT (52 weeks)</td><td>53 %* (n=255)</td><td>62 %* (n=250)</td><td>21 % (n=251)</td></tr><tr><td>Combined Results</td><td>51 %* (n=517)</td><td>63 %*, # (n=519)</td><td>22 % (n=519)</td></tr><tr><td colspan="4">1 results from subjects receiving either 100 mg QD (n=10: patients with serum creatinine &gt; 1.5 and &le; 2.0 mg/dL) or 300 mg QD (n=509) were pooled for analyses. * p &lt; 0.001 vs allopurinol, # p &lt; 0.001 vs 80 mg</td></tr></tbody></table><p>The ability of febuxostat to lower serum uric acid levels was prompt and persistent. Reduction in serum uric acid level to &lt; 6.0 mg/dL (357 &mu;mol/L) was noted by the Week 2 visit and was maintained throughout treatment. The mean serum uric acid levels over time for each treatment group from the two pivotal Phase 3 studies are shown in Figure 1.</p><p>&nbsp;</p><p><strong>Figure 1: Mean Serum Uric Acid Levels in Combined Pivotal Phase 3 Studies</strong></p><p>&nbsp;</p><p><img alt="" width="505" height="335" src="data:image/png;base64,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" /></p><p>&nbsp;</p><p>Note: 509 patients received allopurinol 300 mg QD; 10 patients with serum creatinine &gt; 1.5 and &lt; 2.0 mg/dL were dosed with 100 mg QD. (10 patients out of 268 in APEX study). 240 mg febuxostat was used to evaluate the safety of febuxostat at twice the recommended highest dose. CONFIRMS Study: The CONFIRMS study was a Phase 3, randomized, controlled, 26-week study to evaluate the safety and efficacy of febuxostat 40 mg and 80 mg, in comparison with allopurinol 300 mg or 200 mg, in patients with gout and hyperuricaemia. Two thousand and two hundred-sixty nine (2,269) patients were randomized: febuxostat 40 mg QD (n=757), febuxostat 80 mg QD (n=756), or allopurinol 300/200 mg QD (n=756). At least 65 % of the patients had mild-moderate renal impairment (with creatinine clearance of 30-89 mL/min). Prophylaxis against gout flares was obligatory over the 26-week period. The proportion of patients with serum urate levels of &lt; 6.0 mg/dL (357 &mu;mol/L) at the final visit, was 45 % for 40 mg febuxostat, 67 % for febuxostat 80 mg and 42 % for allopurinol 300/200 mg, respectively. Primary endpoint in the sub-group of patients with renal impairment The APEX Study evaluated efficacy in 40 patients with renal impairment (i.e. baseline serum creatinine &gt; 1.5 mg/dL and &le; 2.0 mg/dL). For renally impaired subjects who were randomized to allopurinol, the dose was capped at 100 mg QD. Febuxostat achieved the primary efficacy endpoint in 44 % (80 mg QD), 45 % (120 mg QD) and 60 % (240 mg QD) of patients compared to 0 % in the allopurinol 100 mg QD and placebo groups. There were no clinically significant differences in the percent decrease in serum uric acid concentration in healthy subjects irrespective of their renal function (58 % in the normal renal function group and 55 % in the severe renal dysfunction group). An analysis in patients with gout and renal impairment was prospectively defined in the CONFIRMS study, and showed that febuxostat was significantly more efficacious in lowering serum urate levels to &lt; 6 mg/dL compared to allopurinol 300 mg/200 mg in patients who had gout with mild to moderate renal impairment (65 % of patients studied). Primary endpoint in the sub group of patients with sUA &ge; 10 mg/dL Approximately 40 % of patients (combined APEX and FACT) had a baseline sUA of &ge; 10 mg/dL. In this subgroup febuxostat achieved the primary efficacy endpoint (sUA &lt; 6.0 mg/dL at the last 3 visits) in 41 % (80 mg QD), 48 % (120 mg QD), and 66 % (240 mg QD) of patients compared to 9 % in the allopurinol 300 mg/100 mg QD and 0 % in the placebo groups.</p><p>In the CONFIRMS study, the proportion of patients achieving the primary efficacy endpoint (sUA &lt; 6.0 mg/dL at the final visit) for patients with a baseline serum urate level of &ge; 10 mg/dL treated with febuxostat 40 mg QD was 27 % (66/249), with febuxostat 80 mg QD 49 % (125/254) and with allopurinol 300 mg/200 mg QD 31 % (72/230), respectively. Clinical Outcomes: proportion of patients requiring treatment for a gout flare APEX study: During the 8-week prophylaxis period, a greater proportion of subjects in the febuxostat 120 mg (36 %) treatment group required treatment for gout flare compared to febuxostat 80 mg (28 %), allopurinol 300 mg (23 %) and placebo (20 %). Flares increased following the prophylaxis period and gradually decreased over time. Between 46 % and 55 % of subjects received treatment for gout flares from Week 8 and Week 28. Gout flares during the last 4 weeks of the study (Weeks 24-28) were observed in 15 % (febuxostat 80, 120 mg), 14 % (allopurinol 300 mg) and 20 % (placebo) of subjects. FACT study: During the 8-week prophylaxis period, a greater proportion of subjects in the febuxostat 120 mg (36 %) treatment group required treatment for a gout flare compared to both the febuxostat 80 mg (22 %) and allopurinol 300 mg (21 %) treatment groups. After the 8-week prophylaxis period, the incidences of flares increased and gradually decreased over time (64 % and 70 % of subjects received treatment for gout flares from Week 8-52). Gout flares during the last 4 weeks of the study (Weeks 49- 52) were observed in 6-8 % (febuxostat 80 mg, 120 mg) and 11 % (allopurinol 300 mg) of subjects. The proportion of subjects requiring treatment for a gout flare (APEX and FACT Study) was numerically lower in the groups that achieved an average post-baseline serum urate level &lt; 6.0 mg/dL,&lt; 5.0 mg/dL or &lt; 4.0 mg/dL compared to the group that achieved an average post-baseline serum urate level &ge; 6.0 mg/dL during the last 32 weeks of the treatment period (Week 20-Week 24 to Week 49 &ndash; 52 intervals). During the CONFIRMS study, the percentages of patients who required treatment for gout flares (Day 1 through Month 6) were 31 % and 25 % for the febuxostat 80 mg and allopurinol groups, respectively. No difference in the proportion of patients requiring treatment for gout flares was observed between the febuxostat 80 mg and 40 mg groups. Long-term, open label extension Studies EXCEL Study (C02-021): The Excel study was a three years Phase 3, open label, multicenter, randomised, allopurinol-controlled, safety extension study for patients who had completed the pivotal Phase 3 studies (APEX or FACT). A total of 1,086 patients were enrolled: febuxostat 80 mg QD (n=649), febuxostat 120 mg QD (n=292) and allopurinol 300/100 mg QD (n=145). About 69 % of patients required no treatment change to achieve a final stable treatment. Patients who had 3 consecutive sUA levels &gt; 6.0 mg/dL were withdrawn. Serum urate levels were maintained over time (i.e. 91 % and 93 % of patients on initial treatment with febuxostat 80 mg and 120 mg, respectively, had sUA &lt; 6 mg/dL at Month 36). Three years data showed a decrease in the incidence of gout flares with less than 4 % of patients requiring treatment for a flare (i.e. more than 96 % of patients did not require treatment for a flare) at Month 16-24 and at Month 30-36. 46 % and 38 %, of patients on final stable treatment of febuxostat 80 or 120 mg QD, respectively, had complete resolution of the primary palpable tophus from baseline to the Final Visit. FOCUS Study (TMX-01-005) was a 5 years Phase 2, open-label, multicenter, safety extension study for patients who had completed the febuxostat 4 weeks of double blind dosing in study TMX-00-004. 116 patients were enrolled and received initially febuxostat 80 mg QD. 62 % of patients required no dose adjustment to maintain sUA &lt; 6 mg/dL and 38 % of patients required a dose adjustment to achieve a final stable dose. The proportion of patients with serum urate levels of &lt; 6.0 mg/dL (357 &mu;mol/L) at the final visit was greater than 80 % (81-100 %) at each febuxostat dose. During the phase 3 clinical studies, mild liver function test abnormalities were observed in patients treated with febuxostat (5.0 %). These rates were similar to the rates reported on allopurinol (4.2 %) (see section 4.4). Increased TSH values (&gt; 5.5 &mu;IU/mL) were observed in patients on long-term treatment with&nbsp;febuxostat (5.5 %) and patients with allopurinol (5.8 %) in the long term open label extension studies (see section 4.4). Post Marketing long term studies CARES Study was a multi-centre, randomised, double-blind, non-inferiority trial comparing CV outcomes with febuxostat versus allopurinol in patients with gout and a history of major CV disease including MI, hospitalisation for unstable angina, coronary or cerebral revascularisation procedure, stroke, hospitalised transient ischemic attack, peripheral vascular disease, or diabetes mellitus with evidence of microvascular or macrovascular disease. To achieve sUA less than 6mg/dL, the dose of febuxostat was titrated from 40mg up to 80mg (regardless of renal function) and the dose of allopurinol was titrated in 100mg increments from 300 to 600mg in patients with normal renal function and mild renal impairment and from 200 to 400mg in patients with moderate renal impairment. The primary endpoint in CARES was the time to first occurrence of MACE, a composite of non-fatal MI, non-fatal stroke, CV death and unstable angina with urgent coronary revascularisation. The endpoints (primary and secondary) were analysed according to the intention-to-treat (ITT) analysis including all subjects who were randomised and received at least one dose of double-blind study medication. Overall 56.6% of patients discontinued trial treatment prematurely and 45% of patients did not complete all trial visits. In total, 6,190 patients were followed for a median of 32 months and the median duration of exposure was 728 days for patients in febuxostat group (n 3098) and 719 days in allopurinol group (n 3092). The primary MACE endpoint occurred at similar rates in the febuxostat and allopurinol treatment groups (10.8% vs. 10.4% of patients, respectively; hazard ratio [HR] 1.03; two-sided repeated 95% confidence interval [CI] 0.87-1.23). In the analysis of the individual components of MACE, the rate of CV deaths was higher with febuxostat than allopurinol (4.3% vs. 3.2% of patients; HR 1.34; 95% CI 1.03-1.73). The rates of the other MACE events were similar in the febuxostat and allopurinol groups, i.e. non-fatal MI (3.6% vs. 3.8% of patients; HR 0.93; 95% CI 0.72-1.21), non-fatal stroke (2.3% vs. 2.3% of patients; HR 1.01; 95% CI 0.73-1.41) and urgent revascularisation due to unstable angina (1.6% vs. 1.8% of patients; HR 0.86; 95% CI 0.59- 1.26). The rate of all-cause mortality was also higher with febuxostat than allopurinol (7.8% vs. 6.4% of patients; HR 1.22; 95% CI 1.01-1.47), which was mainly driven by the higher rate of CV deaths in that group (see section 4.4). Rates of adjudicated hospitalisation for heart failure, hospital admissions for arrhythmias not associated with ischemia, venous thromboembolic events and hospitalisation for transient ischemic attacks were comparable for febuxostat and allopurinol.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In healthy subjects, maximum plasma concentrations (Cmax) and area under the plasma concentrationtime curve (AUC) of febuxostat increased in a dose proportional manner following single and multiple doses of 10 mg to 120 mg. For doses between 120 mg and 300 mg, a greater than dose proportional increase in AUC is observed for febuxostat. There is no appreciable accumulation when doses of 10 mg to 240 mg are administered every 24 hours. Febuxostat has an apparent mean terminal elimination halflife (t1/2) of approximately 5 to 8 hours. Population pharmacokinetic/pharmacodynamic analyses were conducted in 211 patients with hyperuricaemia and gout, treated with febuxostat 40-240 mg QD. In general, febuxostat pharmacokinetic parameters estimated by these analyses are consistent with those obtained from healthy subjects, indicating that healthy subjects are representative for pharmacokinetic /pharmacodynamic assessment in the patient population with gout</p><p>&nbsp;</p><p><u>Absorption</u></p><p>Febuxostat is rapidly (tmax of 1.0-1.5 h) and well absorbed (at least 84 %). After single or multiple oral 80 and 120 mg once daily doses, Cmax is approximately 2.8-3.2 &mu;g/mL, and 5.0-5.3 &mu;g/mL, respectively. Absolute bioavailability of the febuxostat tablet formulation has not been studied. Following multiple oral 80 mg once daily doses or a single 120 mg dose with a high fat meal, there was a 49 % and 38 % decrease in Cmax and a 18 % and 16 % decrease in AUC, respectively. However, no clinically significant change in the percent decrease in serum uric acid concentration was observed where tested (80 mg multiple dose). Thus, Febuxostat Tablets may be taken without regard to food. Distribution The apparent steady-state volume of distribution (Vss/F) of febuxostat ranges from 29 to 75 L after oral doses of 10-300 mg. The plasma protein binding of febuxostat is approximately 99.2 %, (primarily to albumin), and is constant over the concentration range achieved with 80 and 120 mg doses. Plasma protein binding of the active metabolites ranges from about 82 % to 91 %.</p><p><u>Biotransformation</u></p><p>Febuxostat is extensively metabolized by conjugation via uridine diphosphate glucuronosyltransferase (UDPGT) enzyme system and oxidation via the cytochrome P450 (CYP) system. Four pharmacologically active hydroxyl metabolites have been identified, of which three occur in plasma of humans. In vitro studies with human liver microsomes showed that those oxidative metabolites were formed primarily by CYP1A1, CYP1A2, CYP2C8 or CYP2C9 and febuxostat glucuronide was formed mainly by UGT 1A1, 1A8, and 1A9.</p><p><u>Elimination</u></p><p>Febuxostat is eliminated by both hepatic and renal pathways. Following an 80 mg oral dose of 14C-labeled febuxostat, approximately 49 % of the dose was recovered in the urine as unchanged febuxostat (3 %), the acyl glucuronide of the active substance (30 %), its known oxidative metabolites and their conjugates (13 %), and other unknown metabolites (3 %). In addition to the urinary excretion, approximately 45 % of the dose was recovered in the faeces as the unchanged febuxostat (12 %), the acyl glucuronide of the active substance (1 %), its known oxidative metabolites and their conjugates (25 %), and other unknown metabolites (7 %).</p><p><u>Renal impairment</u></p><p>Following multiple doses of 80 mg of febuxostat in patients with mild, moderate or severe renal impairment, the Cmax of febuxostat did not change, relative to subjects with normal renal function. The mean total AUC of febuxostat increased by approximately 1.8-fold from 7.5 &mu;g∙h/mL in the normal renal function group to 13.2 &mu;g∙h/mL in the severe renal dysfunction group. The Cmax and AUC of active metabolites increased up to 2- and 4-fold, respectively. However, no dose adjustment is necessary in patients with mild or moderate renal impairment.</p><p><u>Hepatic impairment</u></p><p>Following multiple doses of 80 mg of febuxostat in patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment, the Cmax and AUC of febuxostat and its metabolites did not change significantly compared to subjects with normal hepatic function. No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C).</p><p><u>Age</u></p><p>There were no significant changes observed in AUC of febuxostat or its metabolites following multiple oral doses of febuxostat in elderly as compared to younger healthy subjects.</p><p><u>Gender</u></p><p>Following multiple oral doses of febuxostat, the Cmax and AUC were 24 % and 12 % higher in females than in males, respectively. However, weight-corrected Cmax and AUC were similar between the genders. No dose adjustment is needed based on gender.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Effects in non-clinical studies were generally observed at exposures in excess of the maximum human exposure. Pharmacokinetic modelling and simulation of rat data suggests that, when co-administered with febuxostat, the clinical dose of mercaptopurine/azathioprine should be reduced to 20 % or less of the previously prescribed dose in order to avoid possible haematological effects (see sections 4.4 and 4.5). Carcinogenesis, mutagenesis, impairment of fertility In male rats, a statistically significant increase in urinary bladder tumours (transitional cell papilloma and carcinoma) was found only in association with xanthine calculi in the high dose group, at approximately 11 times human exposure. There was no significant increase in any other tumour type in either male or female mice or rats. These findings are considered a consequence of species specific purine metabolism and urine composition and of no relevance to clinical use. A standard battery of test for genotoxicity did not reveal any biologically relevant genotoxic effects for febuxostat. Febuxostat at oral doses up to 48 mg/kg/day was found to have no effect on fertility and reproductive performance of male and female rats. There was no evidence of impaired fertility, teratogenic effects, or harm to the foetus due to febuxostat. There was high dose maternal toxicity accompanied by a reduction in weaning index and reduced development of offspring in rats at approximately 4.3 times human exposure. Teratology studies, performed in pregnant rats at approximately 4.3 times and pregnant rabbits at approximately 13 times human exposure did not reveal any teratogenic effects</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Excipients for Core:</strong></p><p>1. Lactose NF Fast Low- BMS 35957 2. Avicel PH 102(Microcrystalline Cellulose) 3. Croscarmellose Sodium Type A 4. Hydroxypropyl Cellulose Low-S 5. Colloidal Silicon Dioxide 6. Magnesium Stearate</p><p><strong>Excipients for Film Coating:</strong></p><p>7. Opadry OY-37202 Dark Tan 8. Purified Water Printing ink: Not available.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&minus; Not Applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                − 3 Years/36 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&minus; Store below 30oC.</p><p>&minus; This medicinal product does not require any special storage condition.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Blister Pack: Lidding material: hard tampered Aluminium Foil lid Forming Film: OPA/AL/PVC reel and (OPA: Oriented polyamide, AL: Aluminium Laminated, PVC: Polyvinyl Chloride) Each pack of Agout contains 30 film-coated tablets (40mg- 2 blister strips; 80mg- 3 blister strips; 120mg3 blister strips) per unit carton.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements for disposal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SPIMACO
AlQassim pharmaceutical plant
Saudi Arabia.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                February 2021.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>